Previous Close | 1.1500 |
Open | 1.7500 |
Bid | 1.1500 |
Ask | 1.8500 |
Strike | 45.00 |
Expire Date | 2025-01-17 |
Day's Range | 1.7500 - 1.7500 |
Contract Range | N/A |
Volume | |
Open Interest | 385 |
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncolog
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
A Hawaii court has ordered the manufacturers and distributors of the blood thinner Plavix to pay the state a combined $916 million after finding the companies failed to disclose the efficacy and safety of the medication, the state attorney general said Tuesday. The judgement was issued against Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi. Bristol Myers Squibb and Sanofi said in a joint statement they disagreed with the penalty and plan to appeal.